← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
TANG KEVIN
10% Owner | Chief Executive Officer | Director | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001178579
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 10
- Purchases · 24M
- 13
- Average purchase
- $5.0M
- Median purchase
- $714.8K
- Gross purchase value
- $65.3M
Companies: Aurinia Pharmaceuticals Inc. | Boundless Bio, Inc. | Fulcrum Therapeutics, Inc.
13 SEC accession(s) · 9 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-21 | Boundless Bio, Inc. | BOLD | 10% Owner | $11.9K | Open filing |
| 2026-07-20 | Fulcrum Therapeutics, Inc. | FULC | 10% Owner | $594.7K | Open filing |
| 2026-07-16 | Boundless Bio, Inc. | BOLD | 10% Owner | $155.6K | Open filing |
| 2026-07-15 | Fulcrum Therapeutics, Inc. | FULC | 10% Owner | $891.1K | Open filing |
| 2026-07-13 | Boundless Bio, Inc. | BOLD | 10% Owner | $222.1K | Open filing |
| 2026-07-08 | Boundless Bio, Inc. | BOLD | 10% Owner | $141.9K | Open filing |
| 2026-07-02 | Boundless Bio, Inc. | BOLD | 10% Owner | $268.9K | Open filing |
| 2026-06-29 | Boundless Bio, Inc. | BOLD | 10% Owner | $714.8K | Open filing |
| 2026-06-02 | Aurinia Pharmaceuticals Inc. | AUPH | Chief Executive Officer | Officer | $12.5M | Open filing |
| 2026-03-03 | Aurinia Pharmaceuticals Inc. | AUPH | Director | $12.7M | Open filing |
| 2025-08-05 | Aurinia Pharmaceuticals Inc. | AUPH | Director | $13.6M | Open filing |
| 2025-03-04 | Aurinia Pharmaceuticals Inc. | AUPH | Director | $12.7M | Open filing |
| 2024-12-09 | Aurinia Pharmaceuticals Inc. | AUPH | Director | $10.8M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing | 38.5% (5/13) | 80.0% (4/5) | +5.1% | +3.3% | -5.6% |
| 20D | 5Developing | 38.5% (5/13) | 80.0% (4/5) | +2.1% | +1.8% | -6.5% |
| 60D | 5Developing | 38.5% (5/13) | 20.0% (1/5) | -3.5% | -2.0% | -5.3% |
| 120D | 4Small Sample | 100.0% (4/4) | 75.0% (3/4) | +8.7% | +11.0% | -11.7% |
Research patterns
- First purchase in 12M
- 2/12
- Large purchase ≥ $100k
- 12/13
- Cluster buying · 15D
- 9/13
- Buying the dip
- 1/5
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.